Japanese Journal of Cancer and Chemotherapy最新文献

{"title":"[A Case of Laparoscopic Total Gastrectomy and Enterostomy with R Anastomosis for Advanced Gastric Cancer in an Older Patient].","authors":"Shinsuke Katsuyama, Toru Masuzawa, Keijiro Sugimura, Kiminori Yanagisawa, Go Shinke, Mitsuru Kinoshita, Ryo Ikeshima, Masayuki Hiraki, Yoshiaki Ohmura, Taishi Hata, Yutaka Takeda, Kohei Murata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 85-year-old female underwent an upper gastrointestinal endoscopy revealed a type 4 tumor extending from the lesser curvature to the antecubital area, and stenosis of the pyloric lesion. Histology of the biopsy sample showed adenocarcinoma (tub2). CT revealed thickening of the stomach wall and numerous enlarged lymph nodes. Laparoscopic total gastrectomy, D2 dissection, Roux-en-Y reconstruction, and enterostomy were performed. After resection, the jejunum was removed from the abdominal cavity and transected 25 cm from the ligament of Treitz. An R anastomosis was created 10 cm from the anal side to the esophagojejunostomy anastomosis, and an enterocutaneous fistula tube was inserted from the blind end 10 cm from the R anastomosis. Laparoscopic esophagojejunostomy was performed using the overlap method. The enterocutaneous fistula was guided laparoscopically from the left costal region. Postoperatively, the patient was maintained on a diet with nutritional management via an enterostomy. No postoperative or enterostomy-related complications were observed. The postoperative course was uneventful and the patient was discharged from the hospital on the postoperative day 22. There was no deterioration in the nutritional status after discharge. Pathology results showed Stage Ⅳ, pT4aN3bM1. The patient did not receive chemotherapy per her request.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"323-325"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Young Male Case of Rectosigmoid Adenocarcinoma with Diffuse Peritoneal Metastasis Managed with Palliative Care and Cell-Free and Concentrated Ascites Reinfusion Therapy to Initiate and Transit to Outpatient Systemic Chemotherapy].","authors":"Yozo Suzuki, Masakazu Ikenaga, Kiyotaka Hagihara, Katsunori Matsushita, Toshiki Noma, Yasufumi Sato, Yoshitomo Yanagimoto, Masafumi Yamashita, Junzo Shimizu, Tomono Kawase, Kenzo Akagi, Yujiro Kashiwagi, Naohiro Tomita, Hiroshi Imamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 30s-year-old male complaining of abdominal distension and pain was referred to our hospital. The support by palliative care team was initiated soon after emergency admission. Colonoscopic examination revealed a circumferential ulcerated tumor of rectosigmoid and the tumor was diagnosed as an adenocarcinoma. Contrast-enhanced CT revealed multiple enlarged lymph nodes, diffuse peritoneal nodules and massive ascites, which led us to the diagnosis of advanced rectosigmoid cancer. Because bowel obstruction was not observed, early initiation of systemic therapy was planned. Although abdominal pain was alleviated with analgesics including opioids, discomfort from abdominal distension remained. So, we decided to perform cell-free and concentrated ascites reinfusion therapy(CART). To avoid the delay in the initiation of systemic chemotherapy due the adverse effects of CART, the first systemic chemotherapy was followed by CART. After single CART, the abdominal distention resolved without relapse, and seamless transition to outpatient treatment was made. Although the prognosis of colorectal cancer with diffuse peritoneal dissemination is poor, aggressive adoption of palliative therapy including CART may enable the introduction of systemic chemotherapy and the following alleviation of cancer-related symptoms.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"348-350"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Thyroid Cancer Discovered Incidentally after Breast Cancer Surgery].","authors":"Kenichi Sakurai, Shuhei Suzuki, Keita Adachi, Tomohiro Hirano, Hitomi Kubota, Ayaka Sakamoto, Akiko Osakaya, Shigeru Fujisaki, Toshiko Ono, Taiki Tsuji","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 51-year-old woman. A left breast tumor was detected during a health checkup and the patient was referred to our hospital. Upon arrival, a mobile mass measuring 17 mm in diameter was palpable in the CD region of the left breast. The mammogram showed a sawtooth mass. Ultrasonography revealed a hypoechoic mass with abundant blood flow. Needle biopsy revealed invasive ductal carcinoma. Systemic examination revealed masses in both thyroid lobes, and a fine-needle aspiration cytology diagnosis showed it to be benign. A left circular mastectomy and sentinel lymph node biopsy were performed. Pathological examination revealed a resection margin negative, ER negative, PgR negative, HER2 negative invasive ductal carcinoma, with a tumor diameter of 20 mm and 17.2% Ki-67 positivity. Thirty months after surgery, the left thyroid tumor showed a tendency to grow, and fine-needle aspiration cytology was performed again, which revealed a papillary carcinoma. A left thyroid lobectomy and lymph node dissection were performed. Pathological examination revealed that the patient had papillary thyroid cancer, T1aN0M0=Stage Ⅰ(<55y). Currently, 3 years after surgery, there is no evidence of metastasis or recurrence of either cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"339-341"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Aberrant RNA Splicing Regulation as a Novel Source of Neoantigens].","authors":"Masahiko Ajiro","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>During oncogenesis and proliferation of cancer cells, numerous alterations occur in genomic DNA and mRNA, and these alterations consequently result in the production and presentation of cancer-specific epitopes(neoantigens)on cancer cell surface through the major histocompatibility complex(MHC). These neoantigens then mark cancer cells as\"non-self\"leading to elimination by the immune system. One of the major insights from cancer genome studies is the detection of neoantigens. Some cancer genome mutations produce neoantigens, enhancing the responsiveness to immune checkpoint blockade (ICB)therapies. The tumor mutation burden(TMB)is used as a surrogate metric for the rate of neoantigen production, and practically used as a biomarker to determine suitability of pembrolizumab, an anti-PD-1 ICB. The focus of neoantigen analysis has been on mutations in genomic DNA. However, recent studies revealed cancer-specific mRNA arising from RNA splicing also provides a source of neoantigens. These findings would provide more detailed insights into cancer immune response and improve the predictive accuracy of ICB effects. In this article, recent progress about RNA splicing-associated neoantigens is summarized.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"300-303"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Port Site Recurrence after Laparoscopic Distal Gastrectomy for Advanced Gastric Carcinoma-A Case Report].","authors":"Rama Adikrisna, Taku Akahoshi, Ippei Murata, Masanori Ikota, Tomoyuki Ohta, Kenjiro Kitasato, Sho Mineta, Yoshihiko Tsuruta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 67-year-old female was admitted to our hospital for the diagnosis of gastric cancer with pyloric stenosis. Upper gastrointestinal endoscopy and computed tomography(CT)revealed a type 3 tumor in the prepyloric region without evidence of distant metastasis. Laparoscopic-assisted distal gastrectomy with D2 lymph node dissection was performed, and the final diagnosis was T4(SE)N1M0, Stage ⅢA. Adjuvant therapy was not administered because the patient suffers from schizophrenia. Twelve months after the initial resection, a mass was palpated at the trocar site in the right hypochondriac region. A core needle biopsy was performed, revealing adenocarcinoma. Abdominal CT showed the mass to be localized above the fascia of the abdominal wall, with no evidence of distant metastasis or peritoneal dissemination. The mass was surgically resected, and the final pathology report confirmed port-site recurrence of gastric cancer. Nine months after the second resection, there were no signs of recurrence.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"354-356"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Two Cases of Surgically Performed Radical Resection for Locally Advanced Adenocarcinoma of the Esophagogastric Junction].","authors":"Koji Yasuda, Masaki Naito, Koki Kawakami, Kohki Yamamoto, Hiroki Yamamoto, Atsuki Koyama, Mami Yoshida, Taku Morita, Yurie Kitano, Daiki Shirasu, Ryuhei Noda, Daisuke Inoue, Hitomi Matsuki, Naoki Okada, Naoki Kataoka","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>A treatment policy for esophagogastric junction cancer is not well established in our country. In particular, there is an ongoing debate regarding treatment, including surgical procedures and chemotherapy, for locally advanced cases. Case 1: An 88-year-old male patient with a history of gastric cancer underwent upper gastrointestinal endoscopy, which revealed a type 2 advanced carcinoma on the lesser curvature of the residual stomach cardia. A biopsy confirmed the diagnosis of adenocarcinoma. Chest and abdominal CT showed enlarged lymph nodes, but no distant metastases. Based on the diagnosis of locally advanced adenocarcinoma of the esophagogastric junction(T3N+M0, cStage Ⅲ), laparoscopic total gastrectomy of the residual stomach was performed. During surgery, invasion into the diaphragmatic crus was suspected; therefore, combined resection was performed. Postoperative pathological examination revealed T3, Ly1b, V1b, N1, M0, and pStage Ⅱb. After surgery, the patient developed a mild pancreatic fistula, which improved with conservative treatment and he was discharged. Due to the patient's advanced age, adjuvant chemotherapy was not administered postoperatively, and there was no recurrence or metastasis 2 years after surgery. Case 2: A 68-year-old male patient presented with abdominal pain and a fever. Blood tests revealed elevated inflammatory marker levels. Abdominal CT revealed an abscess cavity in liver segments S6/7 and enlarged nearby lymph nodes, along with thickening of the wall extending from the lower esophagus to the gastric cardia. Gastrointestinal endoscopy revealed an ulcer with irregular surrounding elevation on the lesser curvature of the esophagogastric junction. A biopsy confirmed the diagnosis of adenocarcinoma. The liver abscess was drained, and cytology of the contents revealed no malignancy. Radical resection was performed using a transhiatal and right thoracic approach for a locally advanced adenocarcinoma of the esophagogastric junction(T4aN+M0, cStage Ⅲ). The postoperative pathological examination revealed T3, Ly1b, V1b, N2, M0, and pStage ⅢA. The patient's postoperative course was uneventful, and he was discharged. He is currently being administered adjuvant chemotherapy, and there has been no recurrence or metastasis 18 months after surgery.</p><p><strong>Conclusion: </strong>We report 2 cases of locally advanced adenocarcinoma of the esophagogastric junction that were successfully treated with surgical resection.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"329-332"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Rare Case of Radical Resection for the Synchronous Double Cancer of Primary Pancreatic Squamous Cell Carcinoma and Primary HER2-Positive Gastric Cancer after Multidisciplinary Treatment].","authors":"Takeo Hara, Akinobu Yasuyama, Tomoki Hata, Miho Okano, Osamu Takayama, Yongkook Kim, Haruhiko Imamoto, Junichi Hasegawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 69-year-old man was referred to our hospital due to a rapid increase of HbA1c. Computed tomography(CT)showed a 40 mm hypo vascular tumor in the body of the pancreas, which was diagnosed as pancreatic squamous cell carcinoma by endoscopic ultrasound-fine needle aspiration. Also, esophagogastroduodenoscopy(EGD)revealed a type 2 tumor in the body of the stomach, which was diagnosed as well differentiated gastric cancer. Gemcitabine and S-1(GS)was performed for pancreatic cancer as neoadjuvant chemotherapy. Both pancreatic and gastric cancer were reduced in size once. However, after 9 courses, CT and EGD showed increase in size of gastric cancer. Trastuzumab plus capecitabine and oxaliplatin, followed trastuzumab plus S-1 and oxaliplatin(SOX), was employed for gastric cancer. While the gastric cancer was remarkedly reduced, the pancreatic cancer was increased in size. GS was administered again, but both pancreatic and gastric cancer were increased in size. Finally, trastuzumab plus SOX was employed for gastric cancer, and 60 Gy of radiotherapy followed nab-paclitaxel and gemcitabine(GA)was employed for pancreatic cancer. After that, distal pancreatectomy, total gastrectomy, splenectomy, and cholecystectomy were performed for pancreatic and gastric cancer. Histopathological findings revealed pancreatic squamous cell carcinoma, ypT3N0M0, and pathological response is Grade 2, also gastric cancer, ypT3 N0M0, and pathological response is Grade 2a. Adjuvant chemotherapy with S-1 was administered and is still ongoing.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"317-319"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Successful Combination of Immune Checkpoint Inhibitors and Radiotherapy for MLH1 Gene-Deficient Colon Cancer].","authors":"Yosuke Shimizu, Haruki Sada, Norimitsu Shimada, Masahide Miyata, Takahiro Fukuda, Michie Ono, Tomomasa Fujii, Yoshiyuki Shibata, Sho Taduma, Naoki Tanimine, Hirofumi Tazawa, Takahisa Suzuki, Takashi Onoe, Takeshi Sudo, Hirotaka Tashiro","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 77-year-old woman was diagnosed with advanced transverse colon cancer(poorly differentiated adenocarcinoma)cT3N3H0P0, cStage Ⅲc and underwent extended left hemicolectomy in April 2020. The tumor tissue revealed RAS: wild type, BRAF: mutant type, dMMR(MLH1 deficiency)by immunochemical staining, and MSI-H by CDx. She received CAPOX as adjuvant chemotherapy after surgery. At the end of the 3 courses, she developed abdominal aortic lymph nodes recurrence( diameter 32×18 mm)and began to receive pembrolizumab therapy in August 2020. But the tumor re-grew 6 months after the start of this regimen. However the recurrent lesion was localized, radiation therapy(IMRT: 54 Gy/27 Fr) was added in combination with pembrolizumab. Two months later the tumor had shrunk significantly. As of June 2024, the patient has remained recurrence-free, suggesting that the abscopal effect may have been involved by immuno-radiotherapy in this case.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"342-344"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Successful Chemotherapy with Mechanical Ventilation Support in a Patient with Esophageal Neuroendocrine Carcinoma-A Case Report].","authors":"Norihiro Akimoto, Tsutomu Sato, Yuko Tamura, Akikazu Yago, Hayato Watanabe, Kohei Kasahara, Kenki Segami, Sho Sato, Yukio Maezawa, Toru Aoyama, Norio Yukawa, Aya Saito","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 61-year-old female presented with dyspnea. CT scan revealed an esophageal tumor with airway stenosis, and she was referred to our hospital. During endoscopy, oxygen desaturation necessitated emergency endotracheal intubation and mechanical ventilation. Following tracheostomy placement, a diagnosis of NEC cStage ⅣB was established. IP chemotherapy was initiated. The patient was successfully weaned from mechanical ventilation on hospital day 14. Follow-up CT demonstrated tumor shrinkage, and she was discharged home on day 52. After that, IP therapy was continued and the tracheotomy tube was removed on an outpatient visit. Although the patient underwent up to fourth-line treatment, she died of the underlying disease 1 year and 2 months after the starts of treatment.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"357-359"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Enhancing CAR-T/CAR-NK Cells through by Cytokine Signaling].","authors":"Yuki Kagoya","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Chimeric antigen receptor(CAR)T-cell therapy has already been in the clinic due to its marked efficacy against several hematologic cancers. However, a significant number of patients relapse after a transient response, and the applicable diseases are still limited. Cytokine signaling is one of the most promising targets to enhance the therapeutic efficacy of CAR-T cells. At the same time, several cytokines are closely associated with toxicity, as exemplified by cytokine release syndrome. Here I will present representative findings on cytokines that have been shown to modulate CAR-T cell functions. I will also present our recent studies on how to simultaneously address efficacy and safety issues in CAR-T cell therapy. We will also briefly discuss CAR-NK cells, in which cytokines play an essential role.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"304-309"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}